Atopic dermatitis is an inflammatory skin disease that comprises, along with asthma and allergic rhinitis, the triad of conditions known as the atopic diseases. These conditions are hereditary and are common causes of social and occupational morbidity. Disease mechanisms are uncertain and there are no satisfactory means of prevention or cure. Diagnosis is imprecise due to lack of distinct laboratory tests. Atopic dermatitis has the most pronounced immunologic and pharmacologic aberrancies and we have studied these abnormalities for clues as to basic causative factors. Our long-term objectives are to delineate the basic pathologic mechanisms and to identify a discrete laboratory indicator of the disease. Our studies have compared atopic and normal blood leukocytes. The latter show biochemical similarities to atopioc cells after exposure to mediators such as histamine, prostaglandin E1 and isoproterenol. This model led to our observation of abnormally high cyclic AMP-phosphodiesterase (PDE) in leukocytes of patients with atopic dermatitis and other atopic conditions. This project is focused upon biochemical characterization of the abnormal PDE in atopic leukocytes and on comparative studies of the PDE in normal lymphocytes and monocytes stimulated with histamine and other mediators. This model should provide a means for evaluating the role of phosphorylation and other mechanisms which may lead to abnormal PDE enzyme forms. Studies with inhibitors may provide insight into new pharmacologic modalities for treating atopic dermatitis. Recent investigations have utilized chromatofocusing as a novel means of biochemical identification and have shown two distinct abnormal fractions of PDE activity in atopic leukocytes. Future extensions of these studies should allow clarification of the exact cell source of these enzyme forms and whether they are identical with those in histamine stimulated cells. Collaborative studies of the Basenji-Greyhound dog model of asthma have shown leukocyte cyclic nucleotide abnormalities and elevated PDE similar to atopic humans. Biochemical identification of abnormal PDE along with newly developed specific antibodies to various PDE forms may provide a means of precise diagnostic, and predictive epidemiologic and genetic studies of atopic dermatitis and the other atopic diseases. Cyclic GMP synthesis and metabolism in these cells will be assessed to evaluate the possibility of imbalanced cyclic nucleotide regulation as an alternate cause of functional defects in atopy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI018615-05
Application #
3128044
Study Section
General Medicine A Subcommittee 2 (GMA)
Project Start
1982-05-01
Project End
1988-08-31
Budget Start
1986-09-01
Budget End
1987-08-31
Support Year
5
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
Schools of Medicine
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Hanifin, J M; Chan, S C; Cheng, J B et al. (1996) Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 107:51-6
Chan, S C; Brown, M A; Willcox, T M et al. (1996) Abnormal IL-4 gene expression by atopic dermatitis T lymphocytes is reflected in altered nuclear protein interactions with IL-4 transcriptional regulatory element. J Invest Dermatol 106:1131-6
Toshitani, A; Ansel, J C; Chan, S C et al. (1993) Increased interleukin 6 production by T cells derived from patients with atopic dermatitis. J Invest Dermatol 100:299-304
Chan, S C; Kim, J W; Henderson Jr, W R et al. (1993) Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis. J Immunol 151:3345-52
Chan, S C; Reifsnyder, D; Beavo, J A et al. (1993) Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol 91:1179-88
Li, S H; Chan, S C; Kramer, S M et al. (1993) Modulation of leukocyte cyclic AMP phosphodiesterase activity by recombinant interferon-gamma: evidence for a differential effect on atopic monocytes. J Interferon Res 13:197-202
Chan, S C; Li, S H; Hanifin, J M (1993) Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol 100:681-4
Chan, S C; Hanifin, J M (1993) Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med 121:44-51
Li, S H; Chan, S C; Toshitani, A et al. (1992) Synergistic effects of interleukin 4 and interferon-gamma on monocyte phosphodiesterase activity. J Invest Dermatol 99:65-70
Hanifin, J M; Lloyd, R; Okubo, K et al. (1992) Relationship between increased cyclic AMP-phosphodiesterase activity and abnormal adenylyl cyclase regulation in leukocytes from patients with atopic dermatitis. J Invest Dermatol 98:100S-105S

Showing the most recent 10 out of 22 publications